Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
The Effect of Helminth Infections and Their Treatment on Metabolic Outcomes: Results of a Cluster-Randomized Trial.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review.PLoS neglected tropical diseases · 2023Pooled it
- The effects of helminth infections on the human gut microbiome: a systematic review and meta-analysis.Frontiers in microbiomes · 2023Pooled it
- The Impact of Helminth Infection on the Incidence of Metabolic Syndrome: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Effect of experimental hookworm infection on insulin resistance in people at risk of type 2 diabetes.Nature communications · 2023Trial
- Trial
- The potential threat of Strongyloides spp. to mountain gorillas and public health in Bwindi Impenetrable National Park, Uganda.Parasitology research · 2026Article
- The gut microbiome and metabolome associate with Schistosoma mansoni infection and cardiovascular disease risk in Uganda.Nature communications · 2026Article
- Helminth Coinfections Modulate Disease Dynamics and Vaccination Success in the Era of Emerging Infectious Diseases.Vaccines · 2025Review
- Coevolutionary interplay: Helminths-trained immunity and its impact on the rise of inflammatory diseases.eLife · 2025Review
- Article
- Clinical challenges and technological breakthroughs in helminthic therapy for diabetes.Frontiers in immunology · 2025Review
- Cichlid fishes are promising underutilized models to investigate helminth-host-microbiome interactions.Frontiers in immunology · 2025Review
- Anti-Inflammatory Effects of Helminth-Derived Products: Potential Applications and Challenges in Diabetes Mellitus Management.Journal of inflammation research · 2024Review
- Associations between soil-transmitted helminth infections and physical activity, physical fitness, and cardiovascular disease risk in primary schoolchildren from Gqeberha, South Africa.PLoS neglected tropical diseases · 2023Article
- Helminth Lessons in Inflammatory Bowel Diseases (IBD).Biomedicines · 2023Review
- Negative association between ascaris lumbricoides seropositivity and Covid-19 severity: insights from a study in Benin.Frontiers in immunology · 2023Article
- Comorbidities involving parasitic diseases: A look at the benefits and complications.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Genome-wide analysis of Schistosoma mansoni reveals limited population structure and possible praziquantel drug selection pressure within Ugandan hot-spot communities.PLoS neglected tropical diseases · 2022Article
- Helminth infection modulates number and function of adipose tissue Tregs in high fat diet-induced obesity.PLoS neglected tropical diseases · 2022Article
- Obesity-Mediated Immune Modulation: One Step Forward, (Th)2 Steps Back.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundHelminths may protect against cardiometabolic risk through effects on inflammation and metabolism; their treatment may be detrimental to metabolic outcomes.
methodsIn a cluster-randomized trial in 26 Ugandan fishing communities we investigated effects of community-wide intensive (quarterly single-dose praziquantel, triple-dose albendazole) vs standard (annual single-dose praziquantel, biannual single-dose albendazole) anthelminthic treatment on metabolic outcomes, and observational associations between helminths and metabolic outcomes. The primary outcome, homeostatic model assessment of insulin resistance (HOMA-IR), and secondary outcomes (including blood pressure, fasting blood glucose, lipids) were assessed after 4 years' intervention among individuals aged ≥10 years.
resultsWe analyzed 1898 participants. Intensive treatment had no effect on HOMA-IR (adjusted geometric mean ratio, 0.96 [95% confidence interval {CI}, .86-1.07]; P = .42) but resulted in higher mean low-density lipoprotein cholesterol (LDL-c) (2.86 vs 2.60 mmol/L; adjusted mean difference, 0.26 [95% CI, -.03 to .56]; P = .08). Lower LDL-c levels were associated with Schistosoma mansoni (2.37 vs 2.80 mmol/L; -0.25 [95% CI, -.49 to -.02]; P = .04) or Strongyloides (2.34 vs 2.69 mmol/L; -0.32 [95% CI, -.53 to -.12]; P = .003) infection. Schistosoma mansoni was associated with lower total cholesterol (4.24 vs 4.64 mmol/L; -0.25 [95% CI, -.44 to -.07]; P = .01) and moderate to heavy S. mansoni infection with lower triglycerides, LDL-c, and diastolic blood pressure.
conclusionsHelminth infections improve lipid profiles and may lower blood pressure. Studies to confirm causality and investigate mechanisms may contribute to understanding the epidemiological transition and suggest new approaches to prevent cardiometabolic disease. CLINICAL TRIALS REGISTRATION: ISRCTN47196031.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.